Justification for valsartan and telmisartan prescribing to patients with coronary artery disease and diabetes melitus type 2

dc.contributor.authorKoshkina, Marharyta
dc.contributor.authorКошкіна, Маргарита Володимирівна
dc.date.accessioned2020-11-23T19:08:51Z
dc.date.available2020-11-23T19:08:51Z
dc.date.issued2020-10
dc.description.abstractIntroduction: It is known that there is a need to prescribe blood pressure control drugs to patients with coronary artery disease (CAD). Among them there is the reninangiotensin-aldosterone system blockers group (ARBs). There is evidence that the designation of ARBs improves predictions of the progress of CAD.en_US
dc.identifier.citationKoshkina M. Justification for valsartan and telmisartan prescribing to patients with coronary artery disease and diabetes melitus type 2 / M. Koshkina // ISIC-2020 : [International Scientific Interdisciplinary Conference for medical students and young scientists, Kharkiv, 8–9 October, 2018]: abstract book / KNMU. – Kharkiv, 2020. – P. 70.en_US
dc.identifier.urihttps://repo.knmu.edu.ua/handle/123456789/27474
dc.language.isoenen_US
dc.subjectcoronary artery diseaseen_US
dc.subjecttype 2 diabetes mellitusen_US
dc.titleJustification for valsartan and telmisartan prescribing to patients with coronary artery disease and diabetes melitus type 2en_US
dc.typeThesisen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
вм 2.docx
Size:
13.04 KB
Format:
Microsoft Word XML
Description:

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
11.22 KB
Format:
Item-specific license agreed upon to submission
Description: